Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 14/20 | 0.73 |
| ▸ | AKT1 | P31749 | 4/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211657 | 0.89 | CNKSR1 (0.60) | CNKSR1AKT1SMN1; SMN2PTGER3 | |
| SCHEMBL19867339 | 0.87 | CNKSR1 (0.60) | CNKSR1AKT1SMN1; SMN2PTGER3 | |
| SCHEMBL17211718 | 0.85 | CNKSR1 (0.64) | CNKSR1AKT1SMN1; SMN2PTGER3 | |
| SCHEMBL17200816 | 0.84 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10PTGER3 | |
| SCHEMBL15811509 | 0.84 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10PTGER3 | |
| SCHEMBL15811518 | 0.84 | CNKSR1 (1.00) | CNKSR1AKT1 | |
| SCHEMBL17211669 | 0.84 | CNKSR1 (0.78) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL18148188 | 0.79 | CNKSR1 (0.69) | CNKSR1AKT1PKMHSD17B10BRAF | |
| SCHEMBL15811526 | 0.79 | CNKSR1 (0.69) | CNKSR1AKT1PKMHSD17B10BRAF | |
| SCHEMBL17211652 | 0.76 | CNKSR1 (0.85) | CNKSR1AKT1PKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | CNKSR1 1/4885AKT1 936/4885PKM 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.